Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase

被引：0
|
作者：
Skljarevski, Vladimir [1 ]
Stauffer, Virginia L. [1 ]
Zhang, Qi [1 ]
Detke, Holland C. [1 ]
Millen, Brian A. [1 ]
Yang, Jyun Yan [1 ]
Selzler, Katherine J. [1 ]
Conley, Robert [1 ,2 ]
Aurora, Sheena K. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
来源：
CEPHALALGIA | 2017年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PO-01-197
引用
收藏
页码：339 / 340
页数：2
相关论文
共 50 条
  • [1] Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase
    Skljarevski, Vladimir
    Stauffer, Virginia L.
    Zhang, Qi
    Detke, Holland C.
    Millen, Brian A.
    Yang, Jyun Yan
    Selzler, Katherine J.
    Conley, Robert
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [2] Phase 3 Study (EVOLVE-1) of Galcanezumab in Episodic Migraine
    Stauffer, V. L.
    Zhang, Q.
    Skljarevski, V
    Millen, B.
    Yang, J.
    Selzler, K. J.
    Conley, R.
    HEADACHE, 2017, 57 (08): : 1336 - 1336
  • [3] Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
    Silberstein, Stephen D.
    Stauffer, Virginia L.
    Day, Katie A.
    Lipsius, Sarah
    Wilson, Maria-Carmen
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (1):
  • [4] Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
    Stephen D. Silberstein
    Virginia L. Stauffer
    Katie A. Day
    Sarah Lipsius
    Maria-Carmen Wilson
    The Journal of Headache and Pain, 2019, 20
  • [5] Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
    Stephen D. Silberstein
    Virginia L. Stauffer
    Katie A. Day
    Sarah Lipsius
    Maria-Carmen Wilson
    The Journal of Headache and Pain, 2019, 20
  • [6] Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Subgroup Analyses of Efficacy by Low-Versus High-Frequency of Migraine Headaches
    Silberstein, Stephen
    Stauffer, Virginia L.
    Day, Kathleen A.
    Lipsius, Sarah
    Wilson, Maria-Carmen
    NEUROLOGY, 2019, 92 (15)
  • [7] Phase 3 studies (EVOLVE-1 & EVOLVE-2) of galcanezumab in episodic migraine: subgroup analyses of efficacy by low-versus high-frequency of migraine headaches
    Silberstein, Stephen
    Stauffer, Virginia L.
    Day, Katie
    Zhang, Qi
    Lipsius, Sarah
    Wilson, Maria-Carmen
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [8] Persistence of effect of galcanezumab in patients with episodic or chronic migraine: phase 3, randomized, double-blind, placebo controlled EVOLVE-1, EVOLVE-2 and REGAIN studies
    Aurora, Sheena K.
    Zhang, Qi
    Stauffer, Virginia L.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [9] Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) (vol 20, 75, 2019)
    Silberstein, Stephen D.
    Stauffer, Virginia L.
    Day, Katie A.
    Lipsius, Sarah
    Wilson, Maria-Carmen
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (01):
  • [10] Effect of galcanezumab following double-blind treatment in patients with migraine: results from EVOLVE-1 and EVOLVE-2
    Zhang, Qi
    Morrow, Paula A.
    Stauffer, Virginia L.
    Skljarevski, Vladimir
    Pearlman, Eric M.
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
12345